7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square

History

2018.06  Acquired ISO45001 (Occupational Health and Safety Management System) certification for the first time in the

               Korean pharmaceutical industry

2017.08  MLR-1023, a novel candidate for type 2 diabetes, was selected by the KHIDI(Korea Health Industry Development

               Institute) under the Ministry of Health and Welfare as a project to support the development of advanced medical

               technology.

2017.05  Bukwang Pharmaceutical Co., Ltd. acquired the exclusive right to distribute the domestic co-marketing rights of

               "200 units of Meditoxin", therapeutic botulinum toxin injectable from Eisaikorea.

 

2017.04  Bukwang Pharmaceutical Co., Ltd. announces the conclusion of an exclusive license agreement with Sumitomo

               Dainippon Pharma on lurasidone HCI for Korea

 

2017.02  Bukwang Pharmaceutical Co., Ltd. submitted Phase 2b IND for new diabetic drug candidate, MLR-1023.

 

2017.01  Bukwang Pharmaceutical Co., ‘JM-010’, a treatment of dyskinesia in Parkinson's Disease patients, is approved for

               Orphan Drug Designation from Korea MFDS.

 

2016.06  Dyna Therapeutics Co., Ltd, a newly launched project focused company by Bukwang, is granted worldwide

               exclusive option to license SOL-804.

2016.11  Factory received certificate of The Occupational Health and Safety Management System (OHSAS18001) /

               The Environmental Management System (ISO14001) by Korean Foundation for Quality (IQNet partner).

2016.03  Signs an export agreement with Kalbe International Pte. Ltd. for Dexid Tab.,

               an incrementally modified drug for diabetic neuropathy, in 6 countries in South East Asia

 

2015.07  Invests in Acer Therapeutics, a US bio-venture company specialized in rare disease treatments

 

2015.06   Bukwang Medica, an OTC-specialized subsidiary company, is established with the aim of strengthening

                and diversifying the OTC business

 

2015.05   Invests in a bio/health industry fund established by Medivate Partners

    

2015.04   Bukwang’s subsidiary Contera Pharma ApS receives an approval of “JM-010” phase IIa IND

                from South African authority for the treatment of LID (Levodopa-Induced Dyskinesia)

 

2014.12   Signs a license agreement with Contera Pharma ApS on JM-010, acquiring rights for relevant patented

                technology about treatment of Levodopa-Induced Dyskinesia (LID)

2014.12   Receives award from the Ministry of Science, ICT and Future Planning for contribution

                to the Open Source Software World Challenge 2014

 

2014.11   Acquires a CNS-specialist bio venture company, Contera Pharma ApS, located in Copenhagen, Denmark

 

2014.09   Korea MFDS (Ministry of Food and Drug Safety) approves phase II IND for the new anti-diabetic agent,

                MLR-1023, which is currently co-developed by both Melior (US) and Bukwang (Korea).

2014.09   Levovir® (clevudine) capsules are first exported to Thailand

 

2014.07   Receives an award from the Financial Supervisory Service at The Best Audit Award

 

2014.05   Establishes subsidiary company Bukwang C&C, specialized in ERP system and services

 

2013.11   Receives marketing approval from Korea Ministry of Food and Drug Safety (MFDS)

                for incrementally modified drug “Dexid Tab” to treat diabetic neuropathy

2013.11   Signs a global partnership agreement with TVM Captial, a life science venture capital company in Canada,

                as a strategic collaboration partner

 

2012.11   Invests in EyeGene, a Korean bio-venture company

 

2011.12   IND for phase 1/2a clinical trial of apatinib mesylate in the US is approved by the US FDA

 

2011.04   The main R&D center is newly built next to the main offices in Daebang-dong, Seoul (current location)

 

2010.01   Levovir® (clevudine) is first exported to the Philippines

2009.01   Signs an agreement with LSK BioPartners. Inc. (US), about Apatinib mesylate, acquiring rights for relevant patents

                and technology in Korea, Japan and Europe

 

2008.08   The second factory receives approval as a cGMP facility

 

2008.03   Receives Order of Industrial Service Merit Tin Tower on Taxpayer Day

 

2007.02   Levovir® (clevudine) capsules are launched in Korea

2007.02   Levovir® (clevudine) capsules are awarded the Grand Prize for the 8th Korea New Drug Awards

 

2006.11   Nominated as one of the “200 Best Under a Billion” by Forbes

2006.11   Clevudine (Levovir® capsules) receives marketing approval from the Korean FDA for treatment of type B hepatitis

 

2004.11   Signs an agreement with Eisai (Japan), about transfer of relevant patents and technology for clevudine

 

2000.05   Changes company name to “Bukwang Pharmaceutical Company Limited”

 

2000.03   Invests in a bio-venture firm Anterogen Co., Ltd.

1989.12   The second factory is built in Ansan, Korea

 

1988.08   Bukwang launches IPO

 

1985.04   Becomes the first in Korea to receive approval for KGMP implementation

                in manufacture of pharmaceutical products

 

1962.03   Changes company name to “Bukwang Pharmaceutical Ind, Co., Ltd.”

 

1960.10   Bukwang is established as “Bukwang Trading Company”

1998.02   Signs an agreement with Triangle, based in the US, for technology transfer and marketing

                rights of clevudine

 

1997.01   Selected as Company with Excellent Labor-Management Relationship

 

1996.04   Signs an agreement with University of Georgia and Yale University, for co-development

                and marketing rights of L-FMAU

 

1993.12   The main Research and Development center is built

 

|    ​Korean    |